Abstract
BackgroundTriple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Immune checkpoint inhibitors (ICI) have entered the therapeutic landscape in TNBC, but only a minority of patients benefit....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
